Remove 2029 Remove Healthcare Provider Remove Pharma
article thumbnail

Making Sense of the Latest Changes to the Market Access Landscape

PM360

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders.

article thumbnail

Digitalisation of the clinical trial landscape

European Pharmaceutical Review

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 111
article thumbnail

The Secret Weapon in Pharma Sales Malaysia: Soft Skills

Contrarian Sales Techniques

In pharma sales, knowing your product is essential, but it’s not enough. billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.31% over the next five years[ source ]. This expansion is driven by factors such as an aging population, increasing healthcare expenditure, and a rising prevalence of chronic diseases[ ref ].

Sales 40